ERBB2 and breast cancer: Subsequently, two randomized, phase III trials compared T-DXd versus TPC in HER2-low, unresectable or metastatic BC (NCT03734029/DESTINY-Breast04 and NCT04494425/DESTINY-Breast06, in late lines post-chemotherapy and chemo-naïve post-endocrine therapy, respectively) [16].